Bleakley Financial Group LLC Sells 317 Shares of Natera, Inc. (NASDAQ:NTRA)

Bleakley Financial Group LLC decreased its stake in shares of Natera, Inc. (NASDAQ:NTRA) by 14.3% during the third quarter, HoldingsChannel.com reports. The fund owned 1,898 shares of the medical research company’s stock after selling 317 shares during the period. Bleakley Financial Group LLC’s holdings in Natera were worth $241,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Park Avenue Securities LLC raised its position in shares of Natera by 17.5% in the first quarter. Park Avenue Securities LLC now owns 5,368 shares of the medical research company’s stock valued at $491,000 after purchasing an additional 799 shares during the period. Wealth Enhancement Advisory Services LLC raised its holdings in Natera by 25.0% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 5,776 shares of the medical research company’s stock worth $528,000 after acquiring an additional 1,155 shares during the period. LVW Advisors LLC acquired a new position in Natera during the 1st quarter worth $209,000. Allspring Global Investments Holdings LLC lifted its position in shares of Natera by 19.9% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 863,406 shares of the medical research company’s stock worth $78,967,000 after purchasing an additional 143,246 shares during the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. bought a new stake in Natera during the 1st quarter valued at approximately $33,956,000. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. Piper Sandler reissued an “overweight” rating and issued a $150.00 price objective on shares of Natera in a research report on Friday, September 13th. Leerink Partners increased their price target on shares of Natera from $140.00 to $150.00 and gave the company an “outperform” rating in a report on Thursday, October 17th. Robert W. Baird boosted their price objective on shares of Natera from $117.00 to $120.00 and gave the stock an “outperform” rating in a report on Friday, August 9th. Canaccord Genuity Group increased their target price on shares of Natera from $130.00 to $145.00 and gave the company a “buy” rating in a research note on Tuesday, August 27th. Finally, Stephens restated an “overweight” rating and set a $125.00 price target on shares of Natera in a research note on Friday, August 9th. One research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $124.44.

Insider Activity at Natera

In other Natera news, CEO Steven Leonard Chapman sold 4,084 shares of the business’s stock in a transaction on Monday, July 29th. The stock was sold at an average price of $102.77, for a total value of $419,712.68. Following the transaction, the chief executive officer now owns 206,293 shares of the company’s stock, valued at approximately $21,200,731.61. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Natera news, insider Daniel Rabinowitz sold 1,057 shares of the company’s stock in a transaction on Monday, July 29th. The stock was sold at an average price of $102.77, for a total transaction of $108,627.89. Following the transaction, the insider now owns 206,400 shares of the company’s stock, valued at approximately $21,211,728. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Steven Leonard Chapman sold 4,084 shares of the stock in a transaction on Monday, July 29th. The shares were sold at an average price of $102.77, for a total value of $419,712.68. Following the completion of the transaction, the chief executive officer now owns 206,293 shares in the company, valued at $21,200,731.61. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 49,458 shares of company stock valued at $5,924,920 in the last three months. Corporate insiders own 7.60% of the company’s stock.

Natera Stock Down 1.1 %

Shares of NASDAQ NTRA opened at $118.65 on Thursday. The business has a fifty day moving average of $123.43 and a two-hundred day moving average of $111.03. The company has a debt-to-equity ratio of 0.34, a quick ratio of 4.01 and a current ratio of 4.14. Natera, Inc. has a 52-week low of $36.90 and a 52-week high of $133.54. The stock has a market cap of $14.57 billion, a PE ratio of -38.03 and a beta of 1.53.

Natera (NASDAQ:NTRA) last released its quarterly earnings results on Thursday, August 8th. The medical research company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.69) by $0.39. The firm had revenue of $413.35 million for the quarter, compared to analyst estimates of $343.00 million. Natera had a negative net margin of 21.47% and a negative return on equity of 36.74%. The company’s revenue for the quarter was up 58.1% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.97) earnings per share. As a group, equities research analysts expect that Natera, Inc. will post -1.96 earnings per share for the current fiscal year.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.